The stock of InflaRx N.V. (NASDAQ:IFRX) hit a new 52-week high and has $53.13 target or 8.00 % above today’s $49.19 share price. The 5 months bullish chart indicates low risk for the $1.28 billion company. The 1-year high was reported on Apr, 17 by Barchart.com. If the $53.13 price target is reached, the company will be worth $102.16M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.
The stock decreased 2.71% or $1.37 during the last trading session, reaching $49.19. About 179,203 shares traded or 2.93% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 17, 2018 and is uptrending. It has outperformed by 35.02% the S&P500.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing – GlobeNewswire” on October 30, 2018, also Globenewswire.com with their article: “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” published on January 03, 2019, Globenewswire.com published: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” on February 27, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Seekingalpha.com and their article: “ROTY Recap: 5 Biotech Runners From The Previous Week – Seeking Alpha” published on April 15, 2019 as well as Globenewswire.com‘s news article titled: “InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” with publication date: November 08, 2018.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.28 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.